N-Terminal-proBNP (NT-proBNP) as an indicator of cardiac dysfunction: A study in patients presenting with suspected cardiac disorders

Zeitschrift fur Kardiologie

Volumn 94, Issue 4, 2005, Pages 247-254

  Hess, G ^a   Moecks, J ^a   Zdunek, D ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Cardiac dysfunction; Creatinine; Glomerular filtration rate (GFR); Left ventricular ejection fraction; N terminal pro brain natriuretic peptide; Renal impairment; Thyroid dysfunction

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ANGINA PECTORIS; ARTICLE; CARDIOLOGY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTORY OF MEDICINE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PHYSICAL EXAMINATION; SYMPTOMATOLOGY; THYROID DISEASE;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; BIOLOGICAL MARKERS; COMORBIDITY; FEMALE; GERMANY; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 17744373270     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-005-0205-6     Document Type: Article

References (32)

1. Huldeman GA, Croft JB, Giles WH, Rashidee A (1999) Hospitalization of patients with heart failure; National Hospital Discharge Survey, 1985 to 1995. Am Heart J 137(2):352-360
2. Hoes AW, Mosterd A, Grobbee DE (1998) An epidemic of heart failure? Recent evidence from Europe. Eur Heart J19:L2-9
3. Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22:6A-13A
4. Krum H, Gilbert RE (2003) Demographics and concomitant disorders in heart failure. Lancet 362:147-158
5. The Task Force on Heart Failure of the European Society of Cardiology (1995) Guidelines for the diagnosis of heart failure. Eur Heart J 16:741-751
6. Sundsfjord JA, Thibault G, Larochelle P, Cantin M (1988) Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 66(3):605-610
7. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD (1996) Comparison of atrial natriuretic peptide, b-type natriuretic peptide and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 77:828-831
8. Levin ER, Gardner DG, Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321-328
9. Raizada V, Thakore K, Luo W, McGuire PG (2001) Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 216(1-2):137-140
10. Hall C (2004) Essential biochemistry and physiology of (NT-pro) BNP. European Journal of Heart failure 6:257-260
11. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA (1997) Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): A new marker of cardiac impairment. Clin Endocrinol 47:287-296
12. Hughes D, Talwar S, Squire IB, Davies JE, Ng LL (1999) An immunoluminometric assay for N-terminal probrain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci 96:373-380
13. Clerico A, Del Ray S, Giannessi D (2000) Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: The need for a new generation of immunoassay methods. Clin Chem 46:1529
14. Talwar S, Downie PF, Ng LL, Squire IB (2000) Towards a blood test for heart failure: The potential use of circulating natriuretic peptides. Br J Clin Pharmacol 50:15-20
15. Yeo J, Wu A, Apple F, Kroll M, Christenson R, Lewandrowski K et al (2003) A Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338:107-115
16. Schulz H, Langvik TA, Lund Sagen E, Smith J, Ahmadi N, Hall C (2001) Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest 61:33-42
17. Sagnella GA (2001) Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem 38:83-93
18. Mair J, Hammerer-Lercher A, Puschendorf B (2001) The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 39:571-588
19. Clerico A, Emdin M (2004) Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50(1):33-50
20. Yandle TG, Nicholls GM, Richards AM (2002) Brain natriuretic peptide-Its function and diagnostic application. Clin Biochemist Rev 23:3-21
21. de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 361:9370
22. McCullough PA, Omland T, Maisel AS (2003) B-type natriuretic peptides: a diagnostic breakthrough for clinicians, Vol. 4 No. 2. Reviews in Cardiovascular Medicine 4(2):72-80
23. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R et al (2003) Clinical applications of B-type natriuretic peptide (BNP) testing. European Heart Journal 24:1710-1718
24. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A (2004) Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the propeptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide. Clin Chem Lab Med 42(1): 37-44
25. Bruch C, Schmermund A, Dagres N et al (2002) Tel-Index in coronary artery disease-validation in patients with overall cardiac and isolated diastolic dysfunction. Z Kardiol 91(6): 472-480
26. Koglin J (2000) Pathogenetic mechanisms of cardiac allograft vasculopathy-impact of nitric oxide. Z Kardiol 89(Suppl 9):IX24-IX27
27. Olson MH, Wachtell K, Tuxen C, Hildebrandt P (2004) N-terminal probrain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy. A LIFE study. J Hypertens 22(8):1597-1604
28. Luchner A, Hengstenberg C, Löwel H, Trawinski J, Baumann M, Riegger GAJ et al (2002) N-terminal pro-brain natriuretic peptides after myocardial infarction: A marker of cardio-renal function. Hypertension 39:99-104
29. Wahl HG, Graf S, Renz H, Fassbinder W (2004) Elimination of the cardiac natriuretic peptide (BNP) and N-Terminal proBNP by hemodialysis. Clin Chem (6):1071-1074
30. Ortega O, Gallar P, Munoz M, Rodriguez I, Carreno A, Ortiz M et al (2004) Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in predialysis patients. Nephron Clin Pract 97(4):C125-C30
31. Schultz M, Faber J, Kistorp C, Jarlov A, Pedersen F, Wiinberg N, Hildebrandt P (2004) N-terminal-pro-B-type natriuretic peptide (NT-proBNP) in different thyroid function states. Clin Endocrinol 60(1):54-59
32. Svendstrup Nielsen L, Svanegaard J, Klitgaard NA, Egeblad H (2004) N-terminal-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. European Journal of Heart failure 6(1):63-70